Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Submission enabling readouts expected to increase in
2024-2025 timeframe
INNOVATION
Selected key assets* with submission enabling readouts in 2024-2025
Remibrutinib
CSU
Positive readout for primary analysis¹;
data to be presented at ACAAI 2023
Final (52 weeks) readout and
submission expected in 2024
ScemblixⓇ
1L CML-CP
Readout and submission expected in 2024
PluvictoⓇ
MHSPC
Readout and submission planned
in 20242
OAV-101
SMA IT
Readout expected in 2024;
submission planned in 2025
Pelacarsen
CVRR
Readout and submission expected in 2025
lanalumab
1L and 2L ITP readouts expected in 2025
with submission planned in 2026
Additional hematology and immunology
indications 2026+
*Unprobabilized estimated peak sales of all asset indications in late-stage development:
> USD 1bn
> USD 2bn
Iptacopan
Additional readouts/submissions
expected in 2025/2026+
> USD 3bn
CSU chronic spontaneous urticaria.
reduction. ITP
immune thrombocytopenia.
CML-CP - chronic myeloid leukemia in chronic phase. mHSPC metastatic hormone-sensitive prostate cancer.
1. Double blind treatment period of 24 weeks with primary analysis at 12 weeks. 2. Event-driven trial endpoint.
SMA IT-spinal muscular atrophy intrathecal. CVRR-cardiovascular risk
16 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation